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Abstract  
 
Background: Breast cancer is a worldwide public health concern. Breast cancer now 
ranks first not only in the industrialized world but also in the developing world. In the 
United States, breast cancer is the most common non-skin cancer and the second leading 
cause of cancer-related death in women. In the past fifty years, a woman's lifetime risk of 
breast cancer more than tripled in the United States, to one in seven today. This trend 
parallels a staggering increase of chemicals in the environment. Given the increasing 
number of women in the workforce, it is possible that increases in breast cancer incidence 
may be caused by occupational exposure. 
Methods: Application of literature review results of breast cancer risk factors and 
screening  efforts at workplaces to determine the cost-benefit analyses for applications in 
an occupational medicine practice.  
Results: Review of epidemiologic studies on suspected environmental risk factors for 
breast cancer shows that at risk populations can readily be found in the workplace. 
Effective screening efforts by occupational medicine physicians can reduce mortality in 
the workforce. Although, conclusions drawn here are limited, it is advisable to develop 
national policies to reduce chemical exposures that may be associated with breast cancer. 
Conclusions: Occupational physicians may be an important and appropriate healthcare 
provider with the opportunity to screen on  at risk population, (workforce- female from 
18- 65) and influence a wide range of well established and suspected environmental risk 
factors for breast cancer by incorporating prevention into occupational medicine clinic 
visits. Mammography and the clinical breast exam have a potential to detect suspicious 
lesions and may be implemented in occupational medicine clinics. Integrating screening 
into pre-employment or periodic examinations would expend minimal time and 
reasonable expenses while potentially preventing worker mortality. The integration of 
breast cancer screening into occupational medicine may simultaneously improve worker 
health and increase the value of the occupational medicine physician. 
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                                                     1.0  INTRODUCTION 
 In the United States, breast cancer is the most common non-skin cancer and the 
second leading cause of cancer-related death in women, although each year, a small 
number of men are diagnosed with or die from breast cancer. The breast cancer diagnosis 
rate has increased, however the overall breast cancer death rate has dropped steadily since 
the early 1990s. The incidence of breast cancer is highest in Whites and African Americans 
have higher mortality rates than any other racial or ethnic group in the United States. The 
gap in mortality between African Americans and Whites has widened in recent years. 
(NIH, 2007) The estimated new cases and deaths from breast cancer in the United States in 
2008 are 182,460(female); 1,990 (male) and 40,480 (female); 450 (male) respectively. 
(table 1) ( American Cancer Society, 2008) 
In terms of the absolute number of incident cases, breast cancer now ranks first not 
only in the industrialized world but also in the developing world. The worldwide mortality 
figure for the year 2000 was 370,000. However, there are marked geographical differences, 
with Africa and Asia currently having incidence rates some 10 times lower than those of 
North America and Northern Europe. Studies of migrant populations have long indicated 
that the genetic background only plays a tiny role in these differences. ( DL Davis et al, 
2003) 
Table 1. Estimated New Breast Cancer Cases and Deaths by Sex, US 
    Estimated New  Cases    Estimated Deaths 
  
Both 
Sexes male female 
both 
sexes male female 
2008 184,450 1,990 182,460 40,930 450 40,480 
     2007   180510 2,030               178,480        40 910 450           40 450 
2006 214,640 1,720 212,920 41,430 460 40,970 
2004 217,440 1,450 215,990 40,580 470 40,110 
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                                                         Breast Cancer 
Breast cancer, the result of out-of-control growth of cells of the breast, is a complex 
disease and there are more than 10 types of breast cancer. Eighty percent of all breast 
cancers are fueled by a natural hormone - estrogen. In vitro assays have identified 
approximately 250 chemicals that mimic or interfere with estrogen, which stimulates 
proliferation of estrogen-sensitive breast cancer cells in laboratory studies and presumably 
underlies many of the established breast cancer risk factor. ( Brody JG et al, 2007) 
Hormones seem to play a role in many cases of breast cancer, but just how this 
happens is not fully understood. Suggested DNA mutations related to breast cancer occur 
in single breast cells during a woman's life rather than being inherited. These acquired 
mutations of oncogenes and/or tumor suppressor genes may result from other factors, such 
as radiation or cancer-causing chemicals. So far, the cause of most acquired mutations that 
could lead to breast cancer remains unknown. Most breast cancers have several gene 
mutations that are acquired. (American Cancer Society, 2007) 
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            1.1    Traditional –well established  risk factors of  breast cancer 
Established risk factors are believed to be largely responsible for geographic 
variation in breast cancer rates , both internationally and within the United States. A pattern 
of elevated mortality rates for female breast cancer in the US extending from the Mid-
Atlantic through the Northeastern states has persisted for many years. (DHHS, NIH, NCI, 
2004) The following risk factors are considered well established: 
Age : 
The chance of being diagnosed with breast cancer goes up as a woman gets older. 
 (NIH, 2007) 
Personal history ; 
Breast cancer in one breast increases risk of getting this disease in the other breast. 
Family history :  
A woman’s risk of breast cancer is higher if her mother, sister, or daughter had breast 
cancer, especially at a young age (before age 40). Having other relatives with breast cancer 
on either her mother’s or her father’s side of the family may also increase risk. (NIH, 2007) 
Certain breast changes : 
Having atypical hyperplasia or lobular carcinoma in situ  increases the risk of breast cancer. 
Genetic alterations :  
An estimated 5 to 10 percent of all breast cancers can be attributed to inherited genetic 
factors. Changes in certain genes (BRCA1, BRCA2, and others) increase the risk of breast 
cancer. Some American women - many of whom are descendants of Ashkenazi Jews from 
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Eastern and Central Europe - have an inherited BRCA1 mutation. More than half will be 
diagnosed with breast cancer by age 50. In some BRCA1 families, there is a likelihood of 
developing both breast and ovarian cancers. The BRCA2 genetic mutation also is prevalent 
among families with Ashkenazi backgrounds. Genetic testing can sometimes show the 
presence of specific genetic changes that are related to risk among those with family 
history of breast cancer. Other genes that may be associated with breast cancer are : p53, 
AT, the GADD repair group, the RB suppressor gene, and the HER-2/neu oncogene. (NIH, 
2007) 
Reproductive and menstrual history :   
The older a woman is when she has her first child, the greater her chance of breast cancer. 
Women who began menstruation at an early age (before age 12), went through menopause 
late (after age 55), or never had children also are at an increased risk. Women who take 
menopausal hormone therapy (either estrogen alone or estrogen plus progestin) for 5 or 
more years after menopause also appear to have an increased chance of developing breast 
cancer. Research has been done to determine whether having an abortion or a miscarriage 
affects a woman’s chance of developing breast cancer later. Large, well designed studies 
have consistently shown no link between abortion or miscarriage and the development of 
breast cancer. (NIH, 2007) 
Race :  
Breast cancer occurs more often in white women than Latino, Asian, or African- American 
women. 
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Radiation therapy to the chest : 
Radiation therapy to the chest before age 30 are at an increased risk of breast cancer. 
Studies show that the younger a woman was when she received radiation treatment, the 
higher her risk of breast cancer later in life. (NIH, 2007) 
Breast density : 
 Older women who have mostly dense (not fatty) tissue on a mammogram are at increased 
risk of breast cancer. 
DES (diethylstilbestrol) : 
Women who took DES during pregnancy between 1940 and 1971 have a slightly increased 
risk of breast cancer. Daughters of women who took DES during pregnancy may have a 
slightly increased risk of breast cancer after age 40, also their risk is increased for vaginal 
cancer. (NIH, 2007) 
Obesity : 
Women who are obese, especially after the menopause have an increased risk of 
developing breast cancer because of abnormally high proportion of fat. Body makes some 
of its estrogen in fatty tissue, obese women are more likely than thin women to have higher 
levels of estrogen in their bodies. High levels of estrogen may be the reason that obese 
women have an increased risk of breast cancer. Also, some studies show that gaining 
weight after menopause increases the risk of breast cancer. Excess fat in the waist area may 
affect risk more than the same amount of fat in the hips and thighs. Researchers believe that 
fat cells in various parts of the body have subtle differences in their metabolism that may 
explain this observation. (NIH, 2007) 
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Physical inactivity : 
Women who are physically inactive throughout life appear to have an increased risk of 
breast cancer. Being physically active may help to reduce risk by preventing weight gain 
and obesity.  
Alcohol :   
Some studies suggest that the more alcoholic beverages a woman drinks, the greater her 
risk of breast. cancer. Alcohol decreases the body’s ability to change estrogen into the 
inactive form and therefore, increases risk. (DHHS, NIH, NCI, 2004 ) 
Oral contraceptives and HRT( hormonal replacement therapy). 
Some studies have shown an increased risk of breast cancer in women taking oral 
contraceptives, while other studies have shown no change in risk. (NIH, 2007) 
The Million Women Study in the United Kingdom revealed that all types of 
postmenopausal hormone replacement therapy significantly increased the risk of breast 
cancer, underscoring earlier findings from the Women's Health Initiative study in the 
United States. Another study found that use of HRT after previously being diagnosed with 
breast cancer tripled a woman's risk of recurrence or development of a new breast tumor. 
 Breast Cancer Fund, 2004) 
Interestingly, most women who have these risk factors do not get breast cancer. 
Also, most women who develop breast cancer have no history of the disease in their 
families. Except for growing older, most women with breast cancer have no strong risk 
factors. (Lafranchi et al, 2007) 
 
              
        2.0      ROLE OF HORMONES IN DEVELOPMENT OF BREAST CANCER 
Estrogen target tissues are breast, uterus and ovaries. It is essential for the normal 
growth and development these tissues and it is important for reproduction. It  regulates a 
woman's menstrual cycles and  also helps maintain healthy bones, heart. Estrogen can 
stimulate cell division directly by binding with its receptors. Indirect way of stimulating a 
cell division is more complex and involves levels of receptors of other hormones such as 
progesterone and growth factors. Since estrogen stimulates cell division, it can increase 
the chance of making a DNA copying error in a dividing breast cell. Estrogen can also 
have the effect of making a spontaneous or chemically-induced mutation permanent, 
since it influences the rate of cell division. Also, estrogen has been proved to promote 
breast tumors. 
Stimulating the development of the breast ducts is an important normal function 
of estrogen. However, immature breast cells are particularly sensitive to the effects 
of carcinogens and are more likely to bind them. The immature stem cells are also less 
efficient at repairing damage to DNA caused by carcinogens. Stages when immature 
breast cells are particularly vulnerable to damage by carcinogens include 0- 4 years of 
age, and from puberty to a woman's first full term pregnancy. During pregnancy breast 
cells mature. These changes  protect them against damage caused by carcinogens because 
they bind them less strongly and are more efficient in DNA repair than immature 
cells.(RA Clark et al, 2002) 
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The active estrogen made by the ovaries is metabolized by the liver into an 
inactive form which does not cause the breast cells division. Some of the estrogen is 
transformed into a long-acting that continues to stimulate the breast cells. Women’s 
bodies  differ in production of this  long-acting estrogen, and therefore those  who 
produce more have a higher breast cancer risk.(Lafranchi et al, 2007) The strongest form 
of estrogen made in vivo is called 17-beta estradiol (E2). Estradiol can be changed into 
other forms of estrogen that are not as strong. For example, the form of estrogen called 2- 
hydroxyestrone (2-OHE) is a weak estrogen, while the form called 16-alpha-
hydroxyestrone (16a-OHE) is a stronger estrogen. There is a  concern that the 16a-OHE 
form of estrogen can cause normal breast cells to become cancerous. In some in vitro 
breast cancer studies, cells have been exposed to different environmental contaminants to 
see if they make different amounts of the 16a-OHE and the weaker 2-OHE forms of 
estrogen. Exposure to chemical such as insecticide DDT and the herbicide atrazine, 
caused the cells to make comparatively more of the 16a-OHE form of estrogen that may 
promote the formation of breast tumors. (RA Clark et al, 2002) 
Another hormone implicated in breast cancer development is thyroid hormone. In 
a retrospective case-control study of 2,226 females, researchers found that women with 
primary hypothyroidism had a 61 percent lower risk of developing invasive breast cancer. 
Additionally, women newly diagnosed with breast cancer were 57 percent less likely to 
have under-active thyroid gland condition compared to a control group of healthy 
women. Additionally, breast cancer patients in the study who also had a history of 
hypothyroidism tended to be older when diagnosed and had a less aggressive, slower-
progressing type that was sensitive to estrogen treatment.  
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Nuclear receptors for thyroid hormone and estrogen are part of the "superfamily" 
of receptors that contribute to control cell growth and differentiation. Hormones must 
bind to this family of important proteins to exert their functions, and depending on the 
hormone to which they bind, can either stimulate or inhibit the growth of cells. Thyroid 
hormone and estrogen both share similar pathways in regulating proliferation and growth 
in the target cells, including cancer cells. This well known phenomenon of cross-talk 
between the receptor of these hormones may promote or inhibit thereby determining the 
“fate” of a cell towards either a regulated growth or a cancer. Data suggest a possible 
biologic role for thyroid hormone in the etiology of breast carcinoma and indicate areas 
of research for the prevention and treatment of breast carcinoma. (Cristofanilli M et al, 
2005) 
 
Environmental estrogens or xenoestrogen are naturally occurring (e.g. 
phytoestrogens in plants) or synthetic chemicals that can act like human estrogen made 
by the ovary.  The greatest concern is over synthetic xenoestrogens that are not easily 
broken down, and that can accumulate and be stored in the  fat cells, including breast fat. 
The strength of these xenoestrogens varies; some are ten times weaker than human 
estrogen, while others are a million times weaker. Some xenoestrogens increase cell 
division and thus may contribute to breast cancer risk. (RA Clark et al, 2002) 
Xenoestrogens include: Bisphenol-A, used in plastic food containers and baby 
bottles; polyvinyl chloride (PVC), used extensively in food packaging, as well as in 
medical products, appliances, cars, toys, credit cards and rainwear; pesticides (including 
some forms of DDT) in agriculture; and diethylstilbestrol, a drug prescribed to pregnant 
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women from 1941 to 1971 that doubled the risk of breast cancer for women who were 
exposed to it in utero and who are now over 40 years of age.(Breast Cancer Fund, 2004) 
Other chemicals identified as being weak environmental estrogens include food 
preservatives (BHT and BHA), the industrial detergent by-products nonyl- and 
octaphenol, compounds used in plastics, the food dye Red #3, and the solvent 
formaldehyde which was used in carpet manufacturing, and is still used in making 
plywood.  
There are many unanswered questions about xenoestrogens and breast cancer risk. 
More studies are needed to identify which environmental chemicals are xenoestrogens, to 
determine their strength, since very weak xenoestrogens may not stimulate breast cell 
division. Studies to determine the extent of exposure to xenoestrogens in the home, 
workplace, and environment are also needed.  
There are other chemicals that are not environmental estrogens and affect the 
levels of and types of estrogen in the body. They may affect estrogen metabolism, or they 
may affect the levels of other hormones in the body that control the production and 
release of estrogen from the ovary. Researchers are now examining the amounts of 16a-
OHE and the weaker 2-OHE forms of estrogen in the urine of women with and without 
breast cancer to see if there is any relationship to breast cancer risk. A recent study has 
shown that postmenopausal women with breast cancer have a significantly lower amount 
of the weaker 2-OHE estrogen versus the 16a-OHE estrogen compared to 
postmenopausal women without breast cancer. Women with higher levels of the 16a-
OHE estrogen in their bodies were more at risk for developing breast cancer. (RA Clark 
et al, 2002)  
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          3.0   ENVIRONMENTAL RISK FACTORS OF BREAST CANCER  
Evidence from Epidemiologic environmental pollutants studies 
As many as 50 percent of breast cancer cases remain unexplained by personal 
characteristics and other traditionally-accepted risk factors; epidemiologists and other 
scientists increasingly believe many cases are linked to environmental factors. (Breast 
Cancer Fund, 2004)  In the past fifty years, a woman's lifetime risk of breast cancer more 
than tripled in the United States, to one in seven today. This trend parallels a staggering 
increase of chemicals in the environment:  some of the 85,000 synthetic chemicals in use 
today can be contributing to breast cancer by altering hormone function or gene 
expression.  
Laboratory research identified 216 chemicals among those - environmental 
pollutants that cause breast tumors in animals and may contribute to breast cancer risk by 
damaging DNA, promoting tumor growth, or increasing susceptibility by altering 
mammary gland development. A total of 73 have been present in consumer products or as 
contaminants in food, 35 are air pollutants, 25 have been associated with occupational 
exposures, 29 are produced in the United States in large amounts, often exceeding 1 
million pounds per year. Compounds of interest include, for example, benzene from 
gasoline, polycyclic aromatic hydrocarbons from vehicle exhaust and air pollution, 
disinfection products from chlorinated drinking water, polychlorinated biphenyls, dioxin, 
chlorinated solvents, and some pesticides. (Brody JG et al, 2007)  
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                     3.1    Polycyclic Aromatic Hydrocarbons (PAH) 
 
Formation of PAHs is mainly caused by incomplete combustion of carbon-
containing fuels such as wood, coal, diesel, fat, tobacco, or incense . PAH mixtures and 
some individual PAH chemicals, such as benzo(a)pyrene, are mammary carcinogens in 
laboratory animals. The IARC has evaluated soot and other PAH mixtures as known 
human carcinogens, based primarily on lung and skin cancers, and has identified 
individual PAHs as probable human carcinogens. Major sources of exposure for general 
populations are smoking, air pollution, auto exhaust, diesel, and diet. Dietary sources 
include smoked and grilled foods and foods such as grain that are contaminated by 
ambient air pollution. PAHs have been found in coal tar production plants, coking plants, 
bitumen and asphalt production plants, coal-gasification sites, smoke houses, aluminium 
production plants, coal tarring facilities, and municipal trash incinerators. 
Air pollution and vehicular exhaust also contain numerous other chemicals, 
including some identified as mammary carcinogens or as endocrine disrupting 
compounds that may affect breast cancer risk.  Workers may be exposed to PAHs by 
inhaling engine exhaust and by using products that contain PAHs in a variety of 
industries such as mining, oil refining, metalworking, chemical production, 
transportation, and the electrical industry. (ATDSR, accessed 12/1/07) 
Metabolites of pyrene and DNA adducts have been used as biomarkers of high 
level exposure to PAHs and these biomarkers are also valid markers of low level 
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environmental exposure to PAHs. It was suggested that they should be implemented in 
combination with more traditional techniques for the assessment of general population 
exposure to PAHs from ambient air pollution. (Castano-Vinyals G et al, 2004) 
Susceptibility due to genetic polymorphisms that affect DNA repair in  
interactions with  PAH exposure has been examined in  case-control studies. The Long 
Island breast cancer study is a large population-based study of an association between 
PAHs and breast cancer. Exposure assessment relied on a measure of DNA damage in 
blood drawn near the time of diagnosis. The OR for detectable versus non detectable 
adducts was 1.32 (95% CI, 1.00–1.74). Women with the highest compared with lowest 
PAH-DNA adducts had an approximately 50% higher breast cancer risk (OR=1.51, 95% 
CI, 1.04-2.20), with little or no evidence of substantial confounding because of taking 
into account an extensive list of breast cancer risk factors. The results did not show a 
dose-response relation. However, dose may not be well characterized in this study, 
despite the use of biological measures, because measurements taken after diagnosis may 
not be representative of the etiologic period, and they do not consider the effects of DNA 
repair mechanisms. The relative contributions of environmental sources, active and 
passive smoking, diet, and air pollution—to adduct formation in this study population are 
unclear because of inconsistent association. (Gammon MD  et al, 2002)  
 Shen et al, 2005 reported a statistically nonsignificant additive interaction 
between the DNA base excision repair gene XRCC1 399 Gln allele carriers and PAH-
DNA adducts, only among never smokers (OR = 1.92; 95% CI, 1.2–3.1) with exposure 
and mutant genotype), and no evidence of interaction for codon 194Tr carriers.  
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Using  the population based breast cancer case-control study on Long Island, NY, Terry 
et al, 2004 reported a joint effect of XPD Gln/Gln genotype and adduct levels above the 
median (OR = 1.9; 95% CI, 1.15–3.15) versus Lys/Lys genotype and adducts below the 
median. this study suggests that those individuals with this polymorphism in the XPD 
gene may face an increased risk of breast cancer from PAH-DNA adducts and cigarette 
smoking. Tang et al, 2003 in a much smaller study, found XPD alleles were associated 
with adduct levels in tumor but not nontumor or benign tissue, suggesting a possible role 
in tumor progression. Rundle et al, 2002 found the null variant of the detoxifying gene 
GSTM1 was associated with adduct levels in cases, but not controls. Results suggest that 
the GSTM1 polymorphism plays a role in preventing accumulation of environmental 
damage in breast tissue. Although these results suggest that molecular epidemiology may 
reveal the mechanisms for an association between environmental PAH exposure and 
breast cancer, it will be important to see whether the findings are repeated and extended 
in other studies. 
Two studies relevant to PAHs assessed exposure from residential location 
together with geographic models of air pollution. Bonner et al, 2005 in a study that 
obtained data from the New York State Department of Environmental Conservation for 
Erie and Niagara Counties reported a statistically significant trend (P-trend <.05) for 
higher breast cancer risk among premenopausal and postmenopausal women whose birth 
address was near a monitoring location with higher levels of total suspended particulates 
(TSP) measured since the 1960s. Among postmenopausal women, ORs were found to be 
elevated but statistically unstable for higher TSP at birth, menarche, and first full-term 
pregnancy. The lack of an association at menarche and first full-term pregnancy for 
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premenopausal women could be due to lower TSP levels in recent years, shorter lag time, 
or other factors. Study suggests that exposure in early life to high levels of PAHs may 
increase the risk of postmenopausal breast cancer; however, other confounders related to 
geography cannot be ruled out. 
  Using indicators of industrial density (chemical, metal fabricating, and other 
specific types of industry) and traffic density over a 20-year period, Lewis-Michl et al, 
1996 reported higher risk associated with living in areas with air pollution from industrial 
facilities, with the OR excluding 1 for Nassau County (OR = 1.61; 95% CI, 1.06–2.43), 
but not Suffolk County on Long Island, NY. Results for living near high-density traffic 
were inconsistent. 
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                                    3.2  Persistent Organochlorines 
Persistent organochlorine compounds include PCBs, chloroforms, 
trichlorethylane, vinyl chloride, pesticides, insecticides, such as DDT. They are 
environmentally persistent and lipophilic. They are frequently detected in food, soil, and 
dust, concentrate up the food chain, and are found in human breast milk and adipose 
tissue. Residues can be measured in blood and breast tissue, providing a way to quantify 
exposure, although these measures are invasive and expensive; therefore, as a practical 
matter, levels cannot be measured repeatedly in an individual. Specific organochlorine 
compounds, such as for example dieldrin, exhibit varying estrogenic activity. 
Organochlorides, including dioxins, can be naturally  produced in the high temperature 
environment of forest fires, and dioxins have been found in the preserved ashes of 
lightning-ignited fires that predate synthetic dioxins. 
 
 
                                 Polychlorinated biphenyls (PCB) 
 
PCB mixtures have been used for a variety of applications such as  dielectric 
fluids for capacitors and transformers, heat transfer fluids, hydraulic fluids, lubricating 
and cutting oils, and as additives in pesticides, paints, carbonless copy  
paper, adhesives, sealants, plastics, reactive flame retardants, and as a fixative for 
microscopy. They were also used in surgical implants. Their production was banned in 
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the U.S. in the 1970s. Because of bioaccumulation in contaminated rivers in industrial 
areas, the primary source of exposure in general populations is from fish. PCBs 
accumulate in fat and high levels have been found in human breast milk. The US EPA 
and the IARC have determined that PCBs are probably carcinogenic to humans. PCBs 
have been associated with estrogenic, tumor promoting, and immunosuppressive 
activities, all of which are relevant in the development of breast cancer. (Negri E. et al, 
2003). 
by 
functio
duction and 
other to
Several  articles examined the association between PCBs and breast cancer in 
case-control and nested case-control studies. The primary outcome was incident breast 
cancer, some studies examined breast cancer recurrence, survival, or aggressiveness. 
Exposure measures included concentrations of total PCBs, congeners grouped 
nal significance, and individual congeners assessed in blood or adipose tissue. 
In nine studies, of organochlorine exposure and risk of breast cancer in general 
populations, the evidence for an association between total PCB and cancer was 
inconsistent, regardless of the exposure measure.( Wolff MS et al, 2000,  Laden F et al, 
2002,  Zheng T et al, 2000, Raaschou-Nielsen O et al, 2005) No association has been 
observed in studies that used a PCB congener grouping based on enzyme in
xicological aspects. ( Moysich KB et al, 2002, Ward EM et al, 2000) 
The most consistent evidence for the association between PCB exposure and 
breast cancer risk come from studies of genetic polymorphisms effect. PCB exposure 
induces CYP1A1 activity and metabolizes steroid hormones, polycyclic aromatic 
hydrocarbons in humans. PCBs themselves or other xenobiotics can be metabolized to 
carcinogenic intermediates in the presence of the variant genotype (Laden F et al, 2002). 
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       The modifying effect of a polymorphism on the association between PCB and 
breast cancer risk has been most pronounced in the cytochrome P450-1A1(CYP1A1)  
e exon 7 variant). (Zhang Y et al, 2004, Moysich KB et al, 1999, 
Laden F
t cancer 
T, and 
CYP17 genotypes on the association between PCB levels and breast cancer risk. 
gene levels. Three studies have found a higher breast cancer risk associated with higher PCB 
exposures among postmenopausal white women with the CYP1A1-m2 genetic variant  
exposures among postmenopausal white women with the CYP1A1-m2 genetic variant 
(also referred to as th
 et al, 2002) 
In contrast, Li et al, 2005 found a non-significant risk increase among 
premenopausal women with the CYP1A1-m2 variant, but not among postmenopausal 
women, based on smaller numbers than in the other studies. Genotype frequencies 
for CYP1A1 M1- and M3-containing genotypes were higher among African Americans 
than among whites, whereas M2- and M4-containing genotypes were more prevalent 
among whites. Another small study demonstrated a non-significant risk elevation among 
women with the CYP1A1-m1 variant genotype and high PCB levels. However, in general 
data do not support the hypothesis that organochlorines increase the risk of breas
among subgroups of women with specific metabolic genotypes. (McCready et al, 2004) 
Potential effect of environment on p53 gene mutation was reported by Hoyer et al, 2002 
in the study  of  women with variants of the p53 suppressor gene. The highest quartile of 
total PCB exposure was associated with increased risk of breast cancer (OR=3.0; 95% 
95% CI= 0.66–13.62). In the study of mechanisms of susceptibility of xenobiotic 
enzymes, results from Helzlsouer et al, 1999 case-control study nested in a prospective 
cohort did not reveal modifying effects of the GSTM1, GSTT1, GSTP1, COM
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Following three studies have associated high PCB exposure to breast cancer 
recurrence or survival. Muscat et al, 2003 found that high PCB levels were associated 
with an increased risk of breast cancer recurrence (OR = 2.9; 95% CI= 1.02–8.2). Hoyer 
et al, 2000 reported that high PCB levels are significantly associated with risk of death 
among women with estrogen receptor positive (ER1) tumors (OR = 2.5; 95% CI, 1.1–
5.7), and Demers et al, 2002 found that higher levels of PCB were associated with more 
aggressive breast cancer. These studies provide high level of confidence in the validity of 
the exposure measure because of the shorter time interval between exposure and 
outcome, and also suggests the possibility that ongoing exposures may have health 
implications. 
 
                                                    Dioxin 
 
Tetrachlorodibenzo-p-dioxin (TCDD) has no useful purpose and is  produced as 
the unwanted by-products of industrial processes such as the manufacture of PVC, 
pesticide production, incineration, pulp and paper bleaching with chlorine, and the 
smelting and recycling of metals. It is classified by the International Agency for Research 
on Cancer (IARC) as a human carcinogen, based on an increase in cancers at all sites, and 
has multiple endocrine effects. TCDD is a reference chemical for mixtures of dioxins and 
furans produced by combustion and other processes involving chlorine.as reviewed by  
Steenland et al, 2004. Dioxin dissolves easily in fats and as a result can build up in the 
fatty tissues of animals and humans. So animals with high fat contents, such as humans, 
whales, polar bears and dolphins, are particularly susceptible to the build up of dioxin. 
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Primary sources of exposure are dietary fat, particularly milk, fish, and meat (Kogevinas 
et al, 2001). Schecter et al, 1994 estimated that nursing babies exceed the U.S. and 
European standards for safe dose of TCDD in their first year of life.  
The best  evidence of the association between  dioxin and breast cancer comes 
from two studies done in Italy and Russia. The first cohort are community residents 
exposed in  1976 by industrial accident in Seveso, Italy. The most recent report from the 
Seveso accident includes 981 women who were infants to 40 years of age at the time of 
the accident and lived in the two most contaminated zones. (Warner M et al, 2002) 
TCDD was measured in serum collected between 1976 and 1981 and standardized to 
represent 1977 levels. Results showed a 2- fold increase in breast cancer incidence in 
1976 to 1998 associated with a 10-fold increase in serum TCDD, based on 15 cases in a 
cohort of 981 women. Bertazzi PA et al, 1993 followed-up cohort in 15- year mortality 
study that assessed exposure by zone of residence and showed non-significantly lower 
breast cancer incidence through 1986 among older women (RR = 0.7; 95% CI, 0.3–
1.5)52 and lower mortality through 1991. This cohort will continue to provide 
information on breast cancer risk association with dioxin because these women are still 
young.  
The second cohort comes from the occupational exposure in a chemical plant in 
Chapaevsk, Russia. This  cohort of workers have been exposed during production of 
herbicides. Revich et al, 2001 reported elevated breast cancer mortality (SMR = 2.1; 95% 
CI, 1.6–2.7) among women living near the chemical plant compared with surrounding 
regions.  
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In an early report by Manz et al,.1991 on a cohort of German herbicide workers, 
showed elevated female breast cancer mortality, although only 7% of the women workers 
were in the high exposure locations. Flesch-Janys D et al, 1999 follow- up reports from 
this cohort used a more sophisticated exposure model based on biological measures and 
integrating exposure over time. The incidence was found to be significantly elevated 
(standardized incidence ratio [SIR] = 1.84; 95% CI, 1.17–2.67) in comparison with the 
regional population. .  
Only one study, Warner et al, 2002 of breast cancer and dioxin, was adequately 
controlled for confounding by established risk factors. Kogevinas et al, 1997 compared 
exposed women and a similarly employed nonexposed group and Flesch-Janys et al, 
1999 compared risk across exposures within the cohort. Both strategies reduce potential 
confounding. Comparisons of occupationally exposed women with general populations 
are problematic because women factory workers likely differ from white and pink-collar 
workers and nonemployed women with regard to many factors related to breast cancer.  
 
Dichloro-diphenyl-trichloroethane(DDT)/Dichloro-diphenyl-dichloroethylene(DDE)  
 
DDT is a pesticide once widely used to control insects. It is a white, crystalline 
solid with no odor or taste. DDE levels are considered a measure of exposure to DDT and 
to DDE from food and the environment, with DDE being the predominant exposure in 
the U.S. since 1972, when DDT was banned, but is still used in some countries . DDE 
(dichlorodiphenyldichloroethylene) and DDD (dichloro-diphenyl-dichloroethane) are 
chemicals similar to DDT that contaminate commercial DDT preparations. 
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In the early 1990s positive findings  triggered new investigations, however 
reviewed studies of DDT/ DDE and dieldrin by Snedeker et al, 2001, Moysich et al, 1999 
and Negri et al, 2003 concluded  that existing research strategies in 2002 through 2003 
provided conflicting and mostly negative evidence. From 2006 research provides 
potential new evidence regarding PCBs, new findings for dioxin, essentially unchanged 
conclusions for DDT/DDE, and a few new results for other organochlorine pesticides.  
Twenty-five reports from case-control studies and nested case-control studies 
published in 2000 to June 2006 examined associations between serum or adipose levels 
of DDT or DDE and breast cancer. A key limitation of the biological markers of 
organochlorine such as DDT/DDE exposure is that they may not accurately measure or 
rank exposure during the years when a tumor was initiated or during critical exposure 
periods in the life cycle when susceptible developing breast tissue was at risk To date, 
blood and adipose techniques are not useful in assessing exposure to nonpersistent 
current-use pesticides. The challenge in studies of these compounds is that exposure is 
usually episodic, so many measurements over a long time would be needed to accurately 
rank subjects on exposure and this cannot be done retrospectively because the new 
pesticides are nonpersistent and no permanent marker of their effect has been identified. 
(Snedeker SM et al, 2001, Birnbaum et al, 2003 ) 
Internationally, a few studies showed elevated risk. In two hospital-based case-
control studies, Charlier et al, 2003, 2004 reported higher risk in European whites with 
detectable DDT (OR = 5.64; 95% CI, 1.81– 17.65) or DDE (OR = 2.21; 95% CI, 1.41–
3.48) in serum. Romieu et al, 2001 found evidence of a dose-response association (P-
trend <.02) with DDE in serum (highest compared with lowest quintile OR = 3.81; 95% 
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CI, 1.14–12.8) in Mexico City. Most studies did not support an association of DDE and 
breast cancer overall or stratified by menopausal status, tumor hormone receptor status, 
parity, breastfeeding, or body mass index.  
 In the US, NIH sponsored one of the largest of the organochlorine studies. The 
Long Island population-based case-control study by Gammon MD et al, 2002 found no 
association between breast cancer risk and the exposure. Similarly, two meta-analyses, 
Laden F et al, 1988 and Lopez-Cervantes M et al, 2004 of the organochlorines did not   
demonstrate an elevated risk. These findings doesn’t support the idea to investigate 
association of breast cancer occurrence and measurement of organochlorine levels near 
the time of diagnosis. 
The promising, although not consistent results are coming from studies of 
polymorphism in metabolism and detoxification of xenobiotics.  Demers et al, 2000 study 
investigated breast cancer aggressiveness  and found a dose related increased risk for 
DDE and large tumors with lymph node involvement in a hospital-based case control 
study. Studies of disease progression have the advantage that biological measures taken 
near diagnosis are more plausibly indicative of exposure during a time relevant to the 
outcome studied.  
From 2000 to June 2006 twenty-one studies reported on 14 organochlorine 
pesticides other than DDT and DDE. Each has been linked to higher risk in at least one of 
the studies. In a nested case-control study of Danish women that averaged 2 serum 
measurements of dieldrin from 1976 and 1983. Hoyer et al, 2000 reported a dose-related 
increased risk of ER negative tumors (OR =7.6; 95% CI, 1.3–4.6 for highest quartile), but 
not ER positive tumors. Also, there was an evidence of  elevated  mortality  in women 
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with ER positive tumors. Study revealed an interaction between higher dieldrin levels and 
a variant of the p53 suppressor gene, although the effect did not reach statistical 
significance.(Hoyer et al, 2002 ) In another study Hoyer et al, 2001  found a dose-related 
increased risk of death with higher dieldrin exposure (OR = 4.6; 95% CI, 1.8–11.5 for 
highest quartile. 
 Long Island study by Gammon et al, 2002 was inconsistent to confirm the 
increased risk with dieldrin exposure and also, .Muscat et al,.2003 found statistically 
unstable elevated risk of recurrence associated with hexachlorobenzene, beta-
hexachlorohexane, and transnonachlor. Raaschou-Nielsen et al, 2005 found a relative risk 
of breast cancer below one in the cohort of Danish women examining the adipose tissue . 
Demers et al, 2000 found associations between tumor size and lymphnode involvement 
for beta- HCH, oxychlordane, and transnonachlor.  
   Given the limitations of already mentioned biomarkers for organochlorines and 
their measurements, it is essential to explore other exposure assessment tools for the 
many pesticides (and other compounds) that are hormonally active or shown to be 
mammary gland carcinogens.  
Residential location and job histories have been the primary alternatives. Residential 
location has the advantage that people spend much of their time at home and occupational 
studies have the advantage of assessing higher exposures than general populations.  
Several studies used the California Department of Pesticide Regulation (DPR) 
database to assess residential or occupational exposure, based on date, location, and other 
characteristics of pesticide application. A cohort study among California teachers found 
no association between breast cancer and exposure estimates based on California 
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pesticide reporting data, (Reynolds P et al, 2004) but California began detailed recording 
of pesticide use only recently (1990), so effects with long latency could not be assessed. 
In a nested case-control study of New York state women, O’Leary et al, 2004 found some 
evidence of increased risk for women living on formerly agricultural land (OR = 1.5; 
95% CI, 0.8–2.9), based on 20 cases, and higher risk for women age 26 years and older at 
the birth of their first child (OR = 6.4; 95% CI, 2.2–18.2, based on 14 cases), suggesting a 
possible interaction with susceptibility due to late differentiation of the mammary gland, 
which occurs during the first pregnancy. Case-control study of agricultural workers did 
not find consistent associations, although there was (nonsignificantly) higher risk among 
younger women with the highest chemical exposures. ( Mills PK  et al, 2005)  
      Historically, there have been developed questionnaire-based exposure  
assessment for traditional breast cancer risk factor such as diet, tobacco use, 
physical activity, pharmaceutical hormone use, childbearing, lactation, menstrual history, 
postmenopausal obesity and weight gain, family history of breast cancer, and other 
possible breast cancer risk factors. However, effort to develop these methods for 
environmental pollutants surprisingly are still insufficient.  
       The Agricultural Health Study by Mills PK et al, 2005 is an important exception, 
with extensive methods developed to ensure the validity of self-reported pesticide use in 
this study. The results provide some evidence of higher risk for farm wives living closest 
to crops (OR = 1.4;95% CI, 0.9–2.0) and for wives whose husbands reported use of 
organochlorines (OR = 1.3; 95% CI, 0.9–2.0) or 2,4,5-TP (OR = 2.0; 95% CI, 1.2–3.2). 
Additional follow-up in this cohort will likely be one of the best sources of information 
on effects of current-use pesticides.  
                                                                        28                                                                          
 
              
Contradictory to the above study, in the Carolina Breast Cancer a population- based case 
control study by Duell et al, 2000 found that farm women did not have higher risk 
overall. Women who reported their presence in a field during or shortly after pesticide 
application were at higher risk compared with farming women who were not exposed 
(OR = 1.8; 95% CI, 1.1–2.8), but their risk was similar to women who had never farmed. 
Women who reported they did not use exposure protection when applying pesticides had 
a higher risk when compared with women who said they did not apply pesticides (OR = 
2.0; 95% CI, 1.0–4.3), but the study may have been susceptible to recall bias.  
   Important contribution to breast cancer investigation are studies that 
identify environmentally sensitive breast changes such as the Crete study by Dolapsakis 
G et al, 2001 of women who went for mammograms in Crete. Those who 
worked with organophosphate and organocarbamate pesticides in greenhouses were at 
significantly higher risk for a variety of nonmalignant breast conditions. Among exposed 
women the rate of malignancy was significantly higher in women ages 40 to 49 years  
than older women. 
 Although, an inconsistent and mostly negative picture arose from evaluation of  
the studies regarding organochlorine pesticides to date, there is good chance to receive 
important information because widespread exposure of girls and women began in the late 
1940s, so women with early-life organochlorine exposure are now in their 50s. Therefore, 
following this birth-cohort over the next 20 years with methods that attempt to capture 
developmental exposures is important. 
 
  
                                                                        29                                                                          
 
              
                         3.3    Drinking Water Disinfection Byproducts  
 
Chlorine is a very active substance and it reacts with naturally occurring 
substances to form compounds known as disinfection byproducts (DBPs). Drinking water 
disinfection byproducts (DBP) have been the subject of numerous cancer assessments, 
including a small number of studies that reported on breast cancer. The most common 
DBPs formed when chlorine is used are trihalomethanes (THMs), and haloacetic acids 
(HAAs). 
MX- 3-chloro-4-(dichloromethyl) -5-hydroxy-2(5<I>H) -furanone, a major 
mutagenic constituent of DBP, is  a cause of  mammary tumors and this evidence  
suggests that breast cancers should be investigated as well. (WHO , 2000) 
Most of the studies of drinking water and breast cancer  suffer from poorly 
controlled confounding and study design. Exception is case-control study done by 
Aschengrau et al, 2003 that is reporting on accidental exposure to perchloroethylene in 
drinking water from distribution pipes. This only population-based study showed that 
increase in risk was not monotonic (adjusted OR = 1.6; 95% CI, 1.1–2.4 for exposure 
>75th percentile). Some misclassification within the exposed group possibly happened 
because the assessment is based on a model of the water distribution system; however, 
participants classified as unexposed were unlikely to be exposed from other water 
sources, a strength in this study that is uncommon in studies of environmental pollutants. 
Possible confounders were extensively evaluated. The results of the study suggest that 
women with the highest PCE exposure levels have a small to moderate increased risk of 
breast cancer. 
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Morris RD et al, 1999 meta-analysis of case-control studies yields a relative risk 
of 1.18 (95% CI, 0.90- 1.54) associated with chlorinated drinking water; the power to 
detect a RR of 1.20 at P < .05 was 0.27. Only 4 of 12 studies in the meta-analysis 
reported on breast cancer. The availability of water quality records dating to the passage 
of the Safe Drinking Water Act in 1974 may provide underutilized opportunities to 
investigate a variety of environmental pollutants and breast cancer at varying geographic 
scales.  
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                                                 3.4   Organic Solvents  
 
Common uses for organic solvents are in dry cleaning (e.g. tetrachloroethylene), 
as paint thinners (e.g. toluene, turpentine), as nail polish removers and glue solvents 
(acetone, methyl acetate, ethyl acetate), in spot removers (e.g. hexane, petrol ether), 
in detergents (citrus terpenes), in perfumes (ethanol), and in chemical syntheses, fuel 
additives (ethylene glycol, methyl ether). These organic solvents were found to sensitize 
breast tissue cells to the effects of hormones estrogens and progestins, therefore 
increasing the risk of breast cancer. Detection of organic solvents in breast milk confirms 
their availability to breast tissue. A number of organic solvents, including common 
chlorinated solvents, such as methylene chloride, have been identified as mammary gland 
carcinogens. Exposure is common in the workplace and at lower levels from air, drinking 
water, and consumer products. Labreche et al, 1977 hypothesize that organic solvents or 
their metabolites initiate or promote breast carcinogenesis through genotoxic or similar 
mechanisms.  
Hypothesis-generating ecologic study of Toxics Release Inventory (TRI) data and 
breast cancer in Texas counties is an example of methods that may identify directions for 
future research. The study found significantly higher incidence associated with 10 of 12 
pollutants. (Coyle YM et al, 2005) Analysis indicated that formaldehyde, methylene 
chloride, styrene, tetrachloroethylene, trichloroethylene, chromium, cobalt, copper, and 
nickel were positively associated with the breast cancer rate. In multiple regression 
models, styrene releases were significantly associated with county-level breast cancer 
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rates for women and men, women, and women age older than 50 years, explaining 9% to 
14% of variance. Analysis were controlled for age, race, and Hispanic ethnicity, but it 
would be useful to know whether variation in TRI exposures among Texas counties is 
strongly correlated with income, education, and reproductive patterns. Styrene was the 
most important environmental toxicant positively associated with invasive breast cancer 
incidence in Texas, likely involving women and men of all ages. It is used in the 
synthetic rubber industry, plastics manufacturing (including production of polystyrene 
food packaging), and is in resins, coatings, paints, tobacco smoke, food, building 
materials, and consumer products. Texas ranks first among states in TRI reported styrene 
releases.  
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                                              3.5  Occupational studies 
 
Given the increasing number of women in the workforce, it is possible that 
increases in breast cancer incidence may be caused by occupational exposure to 
hazardous agents. (Labreche et al, 1997) 
Occupational literature also remains inadequate to evaluate the association between 
organic solvents and breast cancer and the gap becomes obvious analyzing the 
Environmental Health Perspectives 1996 monograph. Nine articles from major 
epidemiologic studies on benzene that have been reviewed (mammary carcinogen in 
animals) contained no reference to breast cancer. Also, historically fewer women than 
men have been employed long-term in industrial jobs characterized by relatively well-
defined chemical exposures, and occupational studies have focused on men, thus 
providing little information regarding breast cancer risks in women.  
Industries using solvents: 
In one of the best-designed studies, Hansen et al, 1999 found an elevated risk of 
breast cancer diagnosis in a population of young women (age <55 years) for all jobs with 
extensive exposure to solvents, and more elevated risk was associated with longer 
duration of employment and longer lag times, as would be expected for a causal relation. 
Risk was approximately doubled for women with more than 10 years in an exposed job 
and 15 years lag time (OR = 1.97; 95% CI, 1.39–2.79). Perchloroethylene is a common 
dry cleaning solvent, so elevated risk among these workers is consistent with the 
Aschengrau et al, 2003 drinking water study. Gardner et al, 2002  found elevated 
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incidence associated with potential exposure to solvents in leather and fur processing (OR 
=3.25; 95% CI, 1.11–9.53) and to solvents and dioxin in glass manufacturing, in which 
risk was found to be more elevated among premenopausal women (OR= 2.70; 95% CI, 
1.20–6.05). 
         Blair et al, 1998 found elevated risk among women who worked with solvents in  
aircraft maintenance (RR = 1.6; 95% CI, 0.9–2.8), and risk was higher for jobs in which  
workers were exposed to freon, solder flux, isopropyl alcohol, trichloroethane, toluene, 
methyl ethyl ketone, and methylene chloride. Many of the specific solvents were correla- 
ted with each other, reducing ability to attribute risk to particular compounds. In a retro-
spective cohort study, Rennix et al, 2005 found higher risk among U.S. Army enlisted 
women in jobs with likely medium or high solvent exposure (IRR =1.48; 95% CI, 
1.01–2.07). Women in the Army are employed more frequently in non-traditional,  
industrial jobs such as auto mechanic and motor transport operators than in the general 
US population, increasing the probability of exposure to industrial chemicals. 
    Band et al, 2000 in a registry-based case control study of Canadian women, 
found elevated incidence among pre- and postmenopausal women in the food industry 
(OR=3.86; 95% CI, 1.06–14.1) and dry cleaning (OR = 5.25; 95% CI, 1.41–19.5). The  
results of this study suggest excess breast cancer risk notably in occupations using solvents 
and pesticides. 
       In a review, Goldberg et al, 2007 found limited evidence of higher risk among women 
in the pharmaceutical industry and beautician trades and little support for increased risk
in textile workers or dry cleaning. 
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     Chang et al, 2003 reported higher incidence in a large cohort of electronics 
factory workers in Taiwan.  However, most of the women had been employed less than 
1 year and 40% had been employed for less than 1 month, may bias the cancer risk 
toward false positive. This suggests no evidence that exposure to chlorinated organic  
solvents at the electronics factory was associated with elevated human cancers, although 
this cohort may yield more useful information in the future. 
        The two assessments of occupational exposure to PAH, benzene and gasoline, vehi-
cular exhaust reported elevated risk of female (Petralia SA et al, 1999) and male (Hansen 
J et al, 1999) breast cancer. Men who worked for more than 3 months in an exposed job 
were particularly at risk if their first exposure was before 40 years of age (OR = 3.7; 95% 
CI, 1.7–7.9 with no lag time; OR = 5.4; 95% CI, 2.4–11.9 with 10 years lag time).  
Hairdressers: 
Lamba et al, 2001 found slightly higher mortality among black (OR = 1.15; 95% 
CI, 0.98–1.30) and white (OR = 1.10; 95% CI, 1.03–1.17) women hairdressers in the 
U.S., and Pollan et al, 1999 found higher risk among Swedish women who were 
hairdressers in 1960 and 1970 (RR = 1.27; 95% CI, 1.11–1.47). 
Nursing and laboratory work: 
Several studies have assessed risks in nursing, health and science laboratories, 
which involve exposures to solvents, therapeutic agents, and the sterilant, ethylene oxide, 
which is a mammary gland carcinogen in animals. However, there is a need to find  
studies of nurses in which findings for chemical exposures are unlikely to be confounded 
by established breast cancer risk factors. 
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In reports from the last 10 years, Band et al, 2000 found elevated risk for nurses in British 
Columbia (OR = 1.54; 95% CI, 1.05,–2.28).  
       Gunnarsdottir et al, 1995 found similarly elevated risk among Icelandic nurses 
(SIR = 1.52; 95% CI, 0.96–2.28 for nurses with 20 years experience) and higher risk 
with lag times of 30 years and longer (SIR = 3.30; 95% CI, 1.12–7.18 for 50 years of 
lag time). They report that nurses were similar to the national comparison population in 
number of children and age at first birth.  
         In a study specific to ethylene oxide, Norman et al, 1995 found an approximately 
2-fold increased risk (SMR ranged from 2.55 (95% CI: 1.31-4.98, P = 0.02) to 1.70 
(95% CI: 0.89-3.23, P = 0.09)) in women who worked in a plant with documented ex- 
posure. The excesses in observed breast cancer incidence diminished over time. 
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            3.6  Epidemiologic environmental pollutants studies:  Conclusion 
 
Weaknesses and limitations 
Limitations found in general include inadequate exposure assessment, lack of access to 
highly exposed and unexposed populations, lack of preclinical markers to identify 
associations that may be obscured by disease latency. Existing technologies are expensive 
to apply in studies large enough to reliably detect the modest risks typical of the 
established breast cancer risk factors. 
The methodological weaknesses are recognizable in many occupational studies. These 
may include: 
1. Inadequate job exposure indices specific for women to asses their experience 
which may differ from men in the same job category.  
2. Confounding will result in studies that compare  breast cancer incidence and 
mortality in general population due to breast cancer risk factors such as  physical 
activity, reproductive history, etc. that differ in blue collar jobs, other jobs and 
those who are not employed.  
3. Some studies use mortality as a breast cancer burden indicator that is inadequate 
given substantial breast cancer survival.  
4. Other weaknesses were apparent in studies that had a short follow up period for 
cancer with a long latency and included women young for breast cancer 
diagnosis.  
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5. Misclassification results from errors in modeling, incomplete historical 
information both for the individual and the setting, and missing or incomplete 
information regarding behaviors that modify exposure (e.g. use of protective gear 
at work or amount of time spent outside). Further, similar misclassification errors 
of women’s exposure arise when employment records or death certificates are 
used rather than more detailed lifetime job histories, because their length of 
employment in a ‘usual’ job may be short. 
6. Another important methodological  problems arise from understating risk due to 
the healthy worker effect or sensitive workers that leave the job due to short term 
illness and cancer is not observed. Similarly, using study groups (exposed and 
control group) from the same polluted region understate the contrast between 
them.  
7. Other difficulties encountered in analysis using large job databases were linking 
job categories to exposure, interpretation of inconsistencies in jobs with 
overlapping exposures, comparison of job classification between studies to 
assume relevant   exposure   due to correlation between chemical exposures. Also, 
in well designed studies there were difficulties to assess consistency of found 
association. 
 
Strength of evidence 
        Despite a relatively small number of studies, the evidence to date generally supports 
an association between breast cancer and polycyclic aromatic hydrocarbons (PAHs), in 
conjunction with certain genetic polymorphisms that lead to suboptimal DNA repair and 
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thus is involved in carcinogen activation. Evidence also supports an association between 
polychlorinated biphenyls (PCBs) which are banned, and breast cancer risk in the 10% to 
15% of women who carry certain genetic variants. The evidence suggests an association 
for organic solvents, the evidence is inconclusive for dioxin and finally, the evidence is 
lacking for organochlorine pesticides. 
  For dioxin the findings are mixed and the only study that controlled for 
confounding, reported an increased breast cancer risk for younger women exposed from 
the Seveso accident. Seveso, Italy, accident is unique and valuable exposure assessment 
tool because the agent, relative dose, and timing of exposure are likely to be known and 
to differ markedly from a comparison population. That why continued follow-up with the 
Seveso cohort is critical. 
Lack of evidence for an association between organochlorine pesticides and breast 
cancer may be due to a true lack of association or to shared methodological weakness 
across a large number of studies. Because these chemicals are banned in many countries 
further research should be a priority only when researchers  have access to novel data that 
resolves earlier methodological problems. Also, the exposure to PAHs is widespread and 
can be reduced, both further study and policies to reduce exposure should be public 
health priorities.  
In summary, there are many chemicals identified in toxicologic research as 
relevant to breast cancer and they have not been investigated in humans. The 
development of better exposure assessment methods for epidemiologic research is needed 
to support evidence from toxicological studies. Job histories and residential histories have 
the potential to assess exposure at multiple points in time, to integrate exposures across 
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time, and to integrate exposures to real-world chemical mixtures. The assessment of 
mixtures, for example, in ambient air, leaves questions concerning which chemical or 
group of chemicals are responsible for observed effects.(e.g. collapse of the World Trade 
Center in 2001 and flooding in New Orleans in 2005) 
         Organic solvents should be a high priority for future breast cancer study. In occu-
pational studies thorough investigation of breast cancer incidence rather than mortality 
is needed, as well as controlling for confounding by physical activity and other 
work-related variables. 
Also, the conclusions drawn here are limited by factors that affect the 
identification of relevant research for review and by weaknesses in the underlying 
studies. 
In the meantime, it is advisable to develop national policies to reduce chemical 
exposures that may be associated with breast cancer. Progress in research on 
environmental pollutants should encourage  strategies to reduce breast cancer risk.  
Future study also must identify exposures from everyday activities, such as pumping gas, 
building materials and consumer products. As a good example of relevant exposure from 
consumer’s products is tobacco smoke (PAH) that was found in recent State of California 
review to be associated with breast cancer in younger women. 
. 
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                                         4.0  METHODS OF SCREENING 
Breast cancer screening is a mode of secondary prevention, a natural extension of 
primary prevention. Because studies of the etiology of breast cancer have failed to 
identify feasible primary prevention strategies suitable for use in the general population, 
reducing mortality from breast cancer through early detection has become a high priority. 
It is widely accepted that screen-detected cancers have a more favorable prognosis. This 
may be related to length bias, true benefit of screening, or both in finding cancers at an 
earlier stage of development. It is also known that screen-detected cancers have favorable 
cellular characteristics. (Leitch et al, 1977). 
The screening methods for breast cancer are numerous. Evaluation of screening 
methods has generally focused on the performance characteristics of the test, i.e., 
sensitivity, specificity, and positive predictive value. For example, the specificity of 
method used is the likelihood of the test being normal when cancer is absent. If 
specificity is low, many false-positive examinations result in unnecessary follow-up 
examinations and procedures. The focus today remains on screen- film mammography as 
a gold standard.  Complete information on available screening methods and opinion of 
Institute of Medicine Report about their effectiveness as a screening tool are summarized 
in the appendix A. 
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                                            4.1   Clinical breast exam 
Clinical breast examination (CBE) refers to the traditional technique of physical 
examination of the breast by a health care provider. For average-risk asymptomatic 
women in their 20s and 30s, it is recommended that CBE be part of a periodic health 
examination, preferably at least every three years. The exam should include breast self-
examination (BSE) instruction for the purpose of gaining familiarity with breast 
composition. 
The examination comprises both systematic inspection and palpation of the 
nipple, breast, and lymph-draining regions in the axillae, supraclavicular and 
infraclavicular fossae. (Albert US et al, 2003) 
The contribution of the clinical breast examination to early detection is difficult to 
determine, but studies show that sensitivity is highly dependent on time taken to do the 
examination. Up to 10 percent of cancers are mammographically silent but evident on 
clinical breast examination. (Knutson et al, 2007)  Screening clinical breast examination 
detects some cancers missed by mammography, but the sensitivity reported in the 
community is lower (28% to 36% ) than in randomized trials (about 54%).  
Weiss et al, 2003 reported that CBE detects about 60% of cancers detected by 
mammography, as well as some cancers not detected by mammography. There have been 
no randomized trials comparing breast cancer mortality between women offered and not 
offered CBE. However, indirect evidence comes from a Canadian study in which women 
were randomly assigned to CBE alone or CBE plus mammography. Women in the two 
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groups had similar rates of nodal involvement at diagnosis and of breast cancer mortality. 
Thus if receipt of mammography averts some deaths from breast cancer, the results of 
this study suggest that CBE has the potential to do so as well.  
Breast self-examination (BSE) has not been shown to be effective in reducing 
breast cancer mortality, but it does increase the number of breast biopsies performed 
because of false-positives. (Elmore et al, 2003)  
CBE appears to be a promising means of averting some deaths from breast cancer. 
The examination by itself is inexpensive, as no special equipment is required. It is easy to 
perform, it can be readily taught to health care providers, and it can be offered 
ubiquitously. CBE should be part of any program for early detection of breast cancer 
worldwide, provided that follow-up medical and oncology care is available. (Albert US et 
al, 2003). Also, it can provide the occasion to raise awareness about breast cancer and to 
provide accurate education on the variety of breast cancer-related topics. 
In a trial that examined the sensitivity and specificity of the test, for 19,965 
women aged 50 to 59 years, sensitivity was 83%, 71%, 57%, 83%, and 77% for years 1, 
2, 3, 4, and 5 of the trial, respectively, and specificity ranged between 88% and 96%. 
PPV, which is the proportion of cancers detected per abnormal examination was 
estimated to be 3% to 4%.   For 25,620 women aged 40 to 49 years, who were examined 
only at entry, the estimated sensitivity was 71%, specificity 84%, and PPV 1.5%. An 
analysis of 752,081 CBEs performed between 1995 and 1998 as part of the National 
Breast and Cervical Cancer Early Detection Program found that 6.9% of CBEs were 
abnormal and that 3.8 invasive cancers and 1.2 cases of DCIS were detected per 1,000 
examinations. Sensitivity was 58.8%, specificity 93.4%, and PPV 4.3%. (NIH, 2007) 
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The USPSTF recommends mammography with or without CBE, and it has 
concluded that there is insufficient evidence to recommend for or against breast cancer 
screening with CBE alone. Recommendations for clinical breast examination were 
modified by adding the advice that women 40 and older schedule annual CBE close to the 
time of, and before, their annual mammograms. (American Cancer Society Guidelines, 
2007) 
Published NIH data showed increased sensitivity of mammography-CBE for 
women aged 60 to 69 years with dense breasts (6.8%), compared with women aged 60 to 
69 years with fatty breasts (1.8%). Specificity was lower for women undergoing both 
(mammography-CBE) screening modalities compared with mammography alone (97% 
vs. 99%). (NIH, accessed October 8, 2007) 
Therefore, after age 40, CBE and BSE are regarded as adjunctive because 
mammography does not achieve perfect sensitivity. (American Cancer Society 
Guidelines,  2007) 
 
 
 
 
 
 
 
 
 
                                                                        45                                                                          
 
              
                                              4.2    Mammography 
The U.S. Preventive Services Task Force recommends mammography for women 
older than 40 years who are in good health, but physicians should consider that sensitivity 
is lower for younger women. Digital mammography is somewhat more sensitive in 
younger women and women with dense breasts, studies are currently underway to 
evaluate the effectiveness of digital mammography in screening of the general 
population. (Knutson et al, 2007) 
Screen-film mammography (SFM) is the current gold standard for breast cancer 
screening. (American Cancer Society, 2003). Overall sensitivity was approximately 75% 
but ranges from 54% to 58% in women younger than 40 years to 81% to 94% in those 
older than 65 years. High breast density is associated 10% to 29% lower sensitivity. 
(Rosenberg RD et al, 1998). The other factors influencing sensitivity are radiologist’s 
interpretation, already mentioned breast  density  that  is affected by age, endogenous and 
exogenous hormones, selective estrogen receptor modulators such as tamoxifen, and diet. 
However, study by Saslow et al, 2007 which proposes guidelines for  use of MRI as a 
screening method, summarized in table A sensitivity and specificity of screening 
modalities and  found sensitivity being lower for mammography than those proposed by 
Rosenberg. The study included at least 6 prospective, nonrandomized studies from the 
Netherlands, the United Kingdom , Canada, Germany, the United States, and Italy. There 
were substantial differences in patient population (age, risk, etc.) and participants in each 
of these 6 studies had either a documented BRCA1 or BRCA2 mutation or a very strong 
family history of breast cancer. Some of the studies included women with a prior 
personal history of breast cancer. 
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Screening mammography reduces breast cancer mortality by about 20% to 35% in 
women aged 50 to 69 years and slightly less in women aged 40 to 49 years at 14 years of 
follow-up. Approximately 95% of women with abnormalities on screening mammograms 
do not have breast cancer with variability based on such factors as age of the woman and 
assessment category assigned by the radiologist.  
Studies comparing full-field digital mammography to screen film have not shown 
statistically significant differences in cancer detection while the impact on recall rates 
(percentage of screening mammograms considered to have positive results) was unclear.  
A pilot trial from the Centers for Disease Control and Prevention Office of Women's 
Health has been completed and found sensitivity 75 % with digital mammography and 
76% with screen film. Specificity was 79% for both. Computer-aided detection and 
diagnosis (CAD) systems consist of computer programs that are designed to recognize 
patterns in images. One study suggested that computer-aided detection increases cancer 
detection rates and recall rates but decreases specificity, while a second, larger study did 
not find any significant differences. (Elmore et al, 2005) 
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                              4.3     Magnetic resonance imaging (MRI) 
Many recently published medical studies have indicated a call for greatly 
expanded use of magnetic resonance imaging  for women who have breast cancer, who 
are at high risk of developing the disease or who have extremely dense breasts on 
mammography. Traditional mammography will most likely always remain the premier 
screening tool for most women. Mammography is very low cost, easy, quick and 
accurate.  
However, MRI is becoming a useful adjunct in breast imaging. Contrast-enhanced 
breast MRI has demonstrated a high sensitivity approaching 98% generally in the 
detection of invasive breast cancer. Due to high sensitivity and potential for "too much 
information," (high false-positive rates) the current guidelines for the use of breast MRI 
from the American Cancer Society recommend MRI screening in high-risk women 30 
years and older who are healthy as an adjunct to screening mammography .High risk is  
defined as a 20 percent to 25 percent or higher risk of developing breast cancer over the 
course of a lifetime. The average lifetime risk for women in the United States is 12 
percent to 13 percent. (Sweeney et al, 2007)   
Other concerns  about the potential of MRI as a screening test include costs, the 
lack of standardized exam techniques and interpretation criteria, the inability of MRI to 
detect microcalcifications, the ultimate sensitivity of the test, variability of equipment. 
Systematic review to assess the effectiveness of adding MRI to mammography with or 
without breast ultrasound and clinical breast examination (CBE) in screening was 
conducted in study by  Lord et al, 2007. Authors found consistent evidence in 5 studies 
that adding MRI provides a highly sensitive screening strategy (sensitivity range: 93-
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100%) compared to mammography alone (25-59%) or mammography plus ultrasound+/-
CBE (49-67%).  
Meta-analysis of the three studies that compared MRI plus mammography versus 
mammography alone showed the sensitivity of MRI plus mammography as 94% (95%CI 
86-98%) and the incremental sensitivity of MRI as 58% (95%CI 47-70%). Incremental 
sensitivity of MRI was lower when added to mammography plus ultrasound (44%, 
95%CI 27-61%) or to the combination of mammography, ultrasound plus CBE (31-33%). 
Estimates of screening specificity with MRI were less consistent but suggested a 3-5-fold 
higher risk of patient recall for investigation of false positive results.  
Specificity may range from 37% to 97%.  Its low specificity means that special 
techniques are needed to develop MRI guidance to biopsy performance, as some lesions 
visible on MRI  are not seen by other imaging modalities.  
Proposed indications for using MRI for screening include strong family history of breast 
cancer, patients with BRCA-1 or BRCA-2 oncogene mutations, evaluation of women 
with breast implants, history of previous lumpectomy or breast  biopsy surgeries, axillary 
metastasis with an unknown primary tumor, very dense or scarred breast tissue 
(American Cancer Society Guidelines, 2003). No studies assessed as to whether adding 
MRI reduces patient mortality, interval or advanced breast cancer rates, and  did not find 
strong evidence that MRI leads to the detection of earlier stage disease. 
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                                                      4.4      Ultrasound 
Prevalence screening studies in women with radiographically dense breasts have 
reported three to four breast cancers per 1,000 women that were detected by ultrasound 
only. In the study done by Saslow et al, 2007 the specificity and sensitivity for ultrasound 
ranged from 91%-96% and 33%- 40% respectively as shown in Table 2. 
An experimental ultrasound technique that measures how easily breast lumps 
compress and bounce back could enable to determine whether a woman has cancer or 
not,  without having to do a biopsy. In  a small study of 80 women, the technique, called 
"elastography," distinguished harmless lumps from malignant ones with nearly 100 
percent accuracy. Cancerous tumors are like stiff springs. Normal tissue and benign 
lesions compress more easily.  
In a clinical trial with Chinese women, UE (ultrasound elastography) was superior 
to sonography and equal or superior to mammography in differentiating benign and 
malignant lesions in the breast. A combination of UE and sonography had the best results 
in detecting cancer and potentially could reduce unnecessary biopsy. (Zhi H  et al, 2007) 
For lesions of all sizes, ultrasound elastography achieved sensitivity of 80%, 
specificity of 93%, positive predictive value of 85.3%, and negative predictive value of 
90.3%. Sensitivity was best for lesions less than 5 mm (90%), while specificity was best 
for lesions over 10 mm (95%). For lesions in BI-RADS categories 3 and 4, sensitivity 
was 68% and specificity was 90%. 
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Table 2. Assessment of sensitivity and specificity of screening modalities in published 
breast MRI screening study . (Saslow et al, 2007) 
 
  
The 
Netherlands Canada United Kingdom Germany US Italy 
No. of centers 
6 1 22 1 13 9
No. of women 
            
           1,909 236 649
 
529 390 106
Age range 
  
25-70 
 
25-65
 
35-49
  
>30  
 
 >25
 
>25
No. of cancers 50 22 35 43 4 8
Sensitivity(%)         
MRI 89 77 77 91 100 100
Mammogram 33 36 40 33 25 16
Ultrasound 
  
n/a 33
 
n/a
 
40 
 
n/a 16
Specificity(%)         
MRI 90 95 81 97 95 99
Mammogram 
 
95 
 
>99 93
 
97 98 0
Ultrasound 
  
n/a 96
 
n/a
 
91 
 
n/a 0
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5.0   ROLE OF OCCUPATIONAL MEDICINE IN BREAST CANCER   
PREVENTION 
Research in the last five years has strengthened the human evidence that not only 
traditional risk factors for breast cancer need to be considered but that  environmental 
pollutants play a role in breast cancer risk as well. Many of these pollutants can be  found 
in the workplace. Therefore, occupational physicians may be suitable healthcare provider 
with the opportunity to screen at risk population, female from 18- 65, and influence wide 
range of presenting risk factors by incorporating prevention into occupational medicine 
clinic visits. 
The examples of two exposures (PAHs and PCBs), for which there is now 
meaningful evidence of an association with breast cancer, can help us build an evidence-
based strategy for preventing breast cancer. Exposure to PAHs is ubiquitous from air 
pollution, tobacco smoke, and cooked food. The observed relative risks for the PAHs are 
similar in range to risks typically associated with many well established risk factors for 
breast cancer, including nulliparity, age at first full-term pregnancy, age at menarche, age 
at menopause, body weight, hormone replacement therapy, and physical inactivity. 
Increased risk observed in susceptible women from exposure to PCB’s is higher than for 
many breast cancer risk factors. Because environmental pollutant exposures are both 
common and avoidable, reducing them should be a public health priority. 
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                        5.1   Estimate of population at risk of breast cancer 
Total US population is approximately 300 million (304,178,766). Total workforce 
is  currently at 146.3 million. Out of this force approximately 48 % are female according 
the US census data for 2008. Using US census information allows to stratify US 
workforce by sex, type of industry (blue and white collar workers) and provide estimate 
of female population that may be at risk of developing breast cancer as shown in the 
tables 3 and 4. 
 
Table 3. U.S. female workforce  in blue collar jobs. 
 
 
blue collar 
workers 
female 
workers  
    % number 
Agriculture, 
forestry, fishing 
and hunting 1958133 20.3                      397501 
Mining 630321 13 81941.73 
Construction 11183930 9.3                  10401055 
Manufacturing 16350948 29.6 4839880.6 
Wholesale trade 4842294 29.7 1438161.3 
Retail trade 16268904 49.2 8004300.8 
Transportation and 
warehousing 6006197 25.1 1507555.4 
Utilities 1137167 21.7 246765.24 
total 58377894   26, 917,161.07
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 Table 4.  U.S. female workforce  in  white collar jobs.
 
  
white 
collar 
workers 
  Female 
workers   
    % number 
Information 3524717 43.7 1540301 
Finance and insurance, and real estate 
and rental and leasing 10241270 55.9 5724870 
Professional, scientific, and 
management, and administrative and 
waste management services: 14301698 43 6149730 
Educational services, and health care 
and social assistance 29491331 74.6 22000533 
Arts, entertainment, and recreation, 
and accommodation and food services 12149998 52.3 6354449 
Other services, except public 
administration 6796996 52.3 3554829 
Public administration 6616727 44.4 2937827 
 total 83122737   48, 262, 539 
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Figure 1.  Population at risk of breast  cancer in the U.S. 
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                           5.2     Workplace screening for breast cancer 
 Healthy worker effect may preclude many female workers from seeing a 
physician regularly. Employees have pre-employment physicals, OSHA-mandated 
physicals, annual physicals, and surveillance exams. The occupational physician can 
examine these patients and consider breast cancer screening simultaneously. Secondly, 
using a  pre-screening questionnaire focused on personal, demographic and occupational 
information can  help target patients at risk for breast cancer. It is advisable to include 
occupational information of employment and non-occupational exposures (hobbies) that 
involved use of organic solvents, polycyclic aromatic hydrocarbons and exposure to 
polychlorinated biphenyls for which the evidence of association with breast cancer has 
been meaningful or suggestive. The occupational clinic would be an ideal place to build a 
tool for registering women with  exposures to the above mentioned chemicals. Such as 
registry for all women followed would help to determine risk estimates with greater 
accuracy. However, this idea may not be supported and welcomed by majority of 
employers due to possible costly litigations. 
 As demonstrated in figure 1, not all women are at the same risk of developing 
breast cancer. The questionnaire should be further expanded by a tool that estimate risk 
of breast cancer over the woman lifetime and create a category of high risk women that 
will benefit from additional and modified screening. Also, cost of screening for these 
women will be higher than cost for majority of women at average risk (13%). It is 
estimated that only 1% to 2% of women have a family history suggestive of the 
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inheritance of an autosomal dominant, high-penetrance gene conferring up to an 80% 
lifetime risk of breast cancer. Features of the family history which suggest the cancers 
may be due to such a high-penetrance gene include 2 or more close (generally first- or 
second-degree) relatives with breast or ovarian cancer; breast cancer occurring before age 
50 years (premenopausal) in a close relative; a family history of both breast and ovarian 
cancer; one or more relatives with 2 cancers (breast and ovarian cancer or 2 independent 
breast cancers); and male relatives with breast cancer. 
 The most frequently used models for estimating breast cancer risk are the Gail  
and Claus Models. The tool allows a health professional to project a woman's individual 
estimate of breast cancer risk over a 5-year period of time and over her lifetime and 
compares the woman's risk calculation with the average risk for a woman of the same 
age. 
The Gail Model incorporates a number of established risk factors to estimate a woman's 
lifetime and 5-year risk for invasive breast cancer. A 5-year risk of 1.7% or higher is 
considered elevated and meets criteria for certain breast cancer prevention trials. While 
an excellent assessment tool for most patients, this model is not recommended for use 
with patients having a strong family history since it excludes some well-established 
factors associated with hereditary breast cancer. The Gail model is the basis for 
the Breast Cancer Risk Assessment Tool available Online from the National Cancer 
Institute. 
The Claus Model provides a more accurate estimate of risk for women with a family 
history of breast cancer by taking into account both maternal and paternal family history, 
second-degree relatives, and their ages at diagnosis. It also factors within the model a 
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family history of ovarian cancer. However, unlike the Gail Model, the Claus Model does 
not include risk factors other than family history. 
In addition to these, The Assessment of Risk Algorithm, developed by the State of 
California, Department of Health Services, provides a basic guide for primary care 
providers to follow and can help identify women at greater risk of breast cancer than the 
general population. The algorithm attempts to incorporate risk factors that have 
epidemiologic evidence of significant risk. It does not include all possible risk factors nor 
does it assess absolute risk for combinations of risk factors. In summary, the algorithm 
provides a qualitative assessment of risk based on personal history, family history, 
medical/pathological/genetic factors, with the outcome of either normal or increased risk 
for breast cancer. (Cancer screening and diagnosing, accessed May 20, 2008 ) 
           Based on expert consensus opinion if the lifetime risk is approximately 20-25% 
identified by these or other models then addition of annual MRI screening is recommen-
ded (figure 1), insufficient evidence exist for lifetime risk of 15-20% and consensus is 
against MRI use is the lifetime risk is at 15%. 
Other risk factors for breast cancer have been identified or proposed but are not 
included for several reasons: because evidence that these factors contribute to breast 
cancer risk is not conclusive, because researchers cannot determine whether these factors 
add useful information to factors already in the model, or because data on other risk 
factors was not available in the research data used to develop the model. Such risk factors 
include: age at menopause, use of birth control pills, high body mass index, a high-fat 
diet, alcohol, radiation exposure, and environmental pollutants. Recently published 
research indicates that breast tissue density can add useful information, but risk models 
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with breast tissue density measurement still need to be validated with additional 
independent studies. Research also indicates that other risk factors, such as use of 
hormone therapy, might improve the tool (NCI, 2008 ). 
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                                 5.3     Cost- effectiveness of screening 
 Employers, particularly large corporations and agencies, must realize that by 
introducing effective work site cancer screening programs they not only fulfill their social 
responsibility to contribute to their employee’s health, but also achieve reductions in 
health care costs, as well as costs associated with ill worker replacement. Chronic 
diseases such as cancer are having a negative impact on employee productivity and 
unhealthy individuals cost more to insure. Thus to keep employees healthy will keep 
them in the low cost insurance group. (Oregon.gov, 2007).  Employers can offer periodic 
screening as an employee health benefit, and/or establish screening programs in the 
workplace that consist of CBE in combination with other modalities of which 
mammography is best established.  
To draw a scenario of such a screening effectiveness, one should consider the 
number of female workers in the US workforce - approximately 75 million (figure 1). 
Only about 2 mammograms out of every 1,000 or 0.2%, lead to a diagnosis of breast 
cancer. Hypothetically, if all women in the US workforce have been screened, it would 
identified about 150, 000  women in the early stage of breast cancer that is more 
responsive to the most current and improved breast cancer therapy  and that  prolongs 
survival time  and saves lifes. It may also result in economic savings if early-stage cancer 
is less expensive to treat  Screen-film mammography (SFM) is the current gold standard 
for breast cancer screening. (American Cancer Society, 2003). The mean total cost per 
woman can be estimated as $124 according published study by Poplack et al, 2005 of 
which $99 was attributable to imaging, and $25 to consultation and/or intervention. The 
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cost of screening of the above mentioned cohort would come to a number of $9,3 billion. 
The mean cost of treatment of breast cancer that includes breast conservation therapy 
(BCT), radiation therapy, adjuvant therapy was at 5 years after diagnosis  $32, 246. 
(Barlow et al, 2001). To treat the 0.2% of cohort for breast cancer has been estimated  to 
$4, 836 900 000. If estimating a value of a life saved to 6 million in the US dollars, rough 
estimate  of saved lifes by mammography screening (~ 30% of mortality reduction) 
would be $270  billion.  Total cost of screening and breast cancer treatment of US female 
workforce then will be $14, 136 900 000 with estimation of savings of those who will be 
successfully treated  $256 billion. 
Employer-sponsored breast cancer screening programs can be provided in the 
following settings: on-site within an employer, mobile unit visiting the employer, and off-
site. Off site visits can be an attractive option for employers that already offer health plan 
benefits to employees that covers expenses incurred by mammography screening 
Providing a time for  women to visit screening facility would serve a public health cause 
to reduce breast cancer mortality. Appendix A provides information on US states 
mammography coverage laws in table 6.  
In study by Kessler et al, 1991 mobile screening mammography was offered to 
3,627 employees of a large corporation in Pennsylvania and Delaware. Women were 
charged $30 for a standard two-view examination. They also received health education 
materials on mammography and breast self-examination. The remaining costs of the 
program were underwritten by the corporation. During this program, 3,627 
mammographic studies were performed; 63 biopsies were recommended. 57 biopsies 
were performed, and 9 cancers were diagnosed. The authors concluded that mobile 
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screening programs at the work site was inexpensive, convenient alternative to more 
traditional screening programs. The advantages of this program were the low cost, the 
relative ease with which the examination can be performed, and the positive role that 
corporate medical personnel assume in encouraging individual and group participation. 
Workplace screening with mobile mammography is one possible approach to the 
convenience barrier. However, fixed-facility workplace screening is a viable alternative 
for any company with a large workforce in one location. (Reynolds HE et al, 1997) 
The cost of mammography itself and of diagnostic work-up are two of the largest 
costs involved (table 5). Therefore, the most efficient approach to providing 
mammography depends on the number of employees receiving mammography; and the 
diagnostic accuracy of mammography and underlying incidence of breast cancer in 
screened population. Especially in population of working women with identifiable risk 
factors, screening is cost-effective because the expenditure required to save a year of life 
through early detection of breast cancer is low compared to other types of health services 
for which employers commonly pay. (Griffiths RI et al, 1998) 
Study by  Schrammel P et al, 1999 evaluating on - site  workplace screening is a 
relatively efficient approach for early detection of breast cancer when compared to off 
site screening or no screening. This study was performed to identify the employer costs 
of breast cancer screening in the workplace, referrals for suspicious findings, and initial 
treatment of malignant disease. Additionally, the costs for these same services, had they 
been obtained outside of a workplace screening program, were estimated. These costs 
were compared to those among a hypothetical cohort of women not enrolled in the 
workplace screening program. 1,416 women participated in the program. Nearly 2,500 
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screening mammograms and approximately 2,773 clinical breast examinations were 
performed, resulting in 292 referrals to physicians outside of the program for additional 
diagnostic procedures and treatment as needed. Mammographic and clinical breast 
examination screening cost $249,041; (table 5) referrals resulting in benign disease or no 
detectable disease cost $185,002; and referrals resulting in malignant disease, followed 
by initial treatment, cost $148,530. Therefore, the total cost was $582,573. 
Approximately 47% of the cost of referrals and initial treatment were due to employee 
lost productivity. Total cost in the hypothetical cohort was $1,067,948 under the 
assumptions that all women received screening outside of the workplace, and that the 
same number of malignancies were detected at the same stage as in the workplace 
program. 
Table 5. CPT Service Codes and Corresponding National Medicare Global Allowable 
Reimbursement Amounts for 2002  
 
 Service CPT code 
National 
Medicare 
Global 
Charge($)
Bilateral screening mammography 76092 81.81
Unilateral diagnostic mammography 76090        73,48 
Bilateral diagnostic mammography 78091 90.5
US 76645 65.52
US-guided biopsy 76942 89.05
Stereotactic biopsy 76095 338.46
Needle placement 19290 64.43
Clinical breast examination 99212 23.17
Surgical consultation 99242 68.05
Breast biopsy, percutaneous, core-needle 19102 102.81
Breast biopsy, percutaneous, automated vacuum-
assisted or rotating biopsy device 19103 187.15
Mammographic guidance for needle placement 76096 75.66
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                                                  5.4    Summary 
Screening for breast cancer can result in early detection of malignancies and lives 
saved. The progress has been made in the US in expanding life-saving access to breast 
cancer screening and treatment but not in substantially reducing incidence. Many of the 
identified risk factors, including family history, age at menarche and menopause, parity, 
breast density, and age at a first full-term pregnancy, cannot be readily modified. 
Pursuing new evidence of risk factors that can be changed is a crucial priority if we are to 
achieve a world without breast cancer. (Devra Lee Davis et al, 2003) 
          The worksite can be a suitable place for both – prevention (screening ) and assess-
ment of cancer risk  as outlined previously. This review supports screening by 
occupational medicine physicians for breast cancer (detection of suspicious lesions) and 
making an appropriate referral. Occupational medicine physicians have the opportu-
nity to detect a breast cancer in a population that may not routinely see a physician and 
may be in higher risk than general population. Focusing a few minutes of the 
examination on breast cancer screening may prevent patient morbidity and mortality.  
Study by  Schrammel P et al, 1999 showed that  workplace screening is a 
relatively efficient approach for early detection of breast cancer .The efficiency could be 
improved with a reduction in the number and cost of unnecessary referrals. That place an 
emphasis on occupational medicine physician to improve his or her breast cancer 
detection knowledge if they were to begin breast cancer screening examinations. 
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           To improve skills of occupational medicine physicians in clinical  and counse-
ling skills (screening mammography) the workshops utilizing standardized patients 
could be a choice. The overall clinical breast exam score increased substantially from 24.8
to 34.7 (P < 0.0001) in study done by Costanza et al, 1999. The basic course cost 
$202 per physician trained. 
 With increased emphasis placed on breast cancer screening by ACOEM in 
cooperation with other breast cancer organizations, it is likely that awareness of breast 
cancer will be raised in the workplace. With education and continued efforts there is a 
hope that  management of large corporations will support comprehensive  breast cancer 
screening, thus fulfill their social responsibility to contribute to their employee’s health. 
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                                   APPENDIX:  TABLE 6 and TABLE 7 
 
 
 TABLE 6.  Potential New Imaging Technologies for Breast Cancer Detection*  
Technology 
Current Level of 
Evidence 
Supporting Use in 
Screening 
FDA 
Approval for 
General 
Clinical Use
FDA Approval 
Specifically for 
Screening 
Screen-film mammography 
(SFM) A Yes Yes 
Full-field digital 
mammography (FFDM) B Yes Yes 
Computer-aided detection with 
SFM B Yes Yes 
Computer-aided detection with 
FFDM B Yes Yes 
Ultrasound (US) B Yes No 
Magnetic resonance imaging 
(MRI) B Yes No 
Novel ultrasound methods 
(Doppler, 3D, compound 
scanning, etc.) C No No 
Computer-aided detection with 
US C No No 
Computer-aided detection with C No No 
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   Table 6 continued           
MRI 
X-ray computer tomography 
(CT) C Yes No 
Scintimammography C Yes No 
Positron emission tomography 
(PET) C Yes No 
Elastography (MR and US) C No No 
Magnetic resonance 
spectroscopy C No No 
Optical imaging C No No 
Optical spectroscopy C No No 
Electrical potential 
measurements C No No 
Electrical impedance imaging C Yes No 
Electronic palpation C No No 
Dedicated breast CT (x-ray, 
US, optical, thermoacoustic) C No No 
Thermography D Yes No 
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  Table 6 continued            
Magnetomammography E No No 
Microwave imaging E No No 
Hall effect imaging E No No 
Key: 
A = Strong clinical evidence for effectiveness in screening; technology is routinely 
used for screening. 
B = Some clinical evidence for effectiveness or equivalence to screen-film 
mammography for screening. 
C = Preclinical data suggest possible promise, but clinical data are sparse or 
nonexistent; more study is needed. 
D = Clinical evidence indicates that modality is ineffective as a screening tool. 
E = Technology is not at the stage that data are available. 
*Adapted with additions and minor changes from Table 2-1, Institute of Medicine 
Report on New Technologies in Breast Imaging, 2001 
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TABLE 7. States with Mammography Screening Coverage Laws 
 
State Code Frequency and Age Requirements
AK 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
AL 6 every two years for 40s or physician rec.; each year for 50+ or 
physician rec.
AR 1 Insurers must offer baseline for ages 35-39, every two years for 
40s, each year 50+, or physician rec.
AZ 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
CA 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
CO 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
CT 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
DC 5 coverage 
DE 1 baseline for ages 35-39, every two years for 40s, each year 
50+ 
FL 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
GA 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
HI 5 annual for 40+, or physician rec.
IA 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
ID 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
IL 5 baseline for ages 35-39, annual for 40+
IN 5 annual for 40+, or physician rec.
KS 4 Covered in accordance with American Cancer Society 
guidelines when reimbursement is provided for lab and X-ray 
services 
KY 1 baseline for ages 35-39, every two years for 40s, each year 
50+ 
LA 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
MA 5 baseline for ages 35-39 and annual for 40+ 
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    Table 7 continued       
MD 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
ME 5 annual for 40+
MI 5 Insurance must offer baseline for ages 35-39, annual for 40+ 
MN 4 if recommended
MO 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec. 
MS other Insurance must offer annual for ages 35+
MT 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
NC 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
ND 5 baseline for ages 35-39, annual for 40+, or physician rec.  
NE 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
NH 1 baseline for ages 35-39, every two years for 40s, each year 
50+ 
NJ 5 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
NM 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
NV 5 baseline for ages 35-39 and annual for 40+ 
NY 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
OH 1 Insurance must offer baseline for ages 35-39, every two years 
for 40s, one if a woman is at least 50 but under 65, or physician 
rec. 
OK 5 baseline for ages 35-39 and annual for 40+ 
OR 5 Annual for 40+, or by referral
PA other annual for 40+, physician rec for under 40
RI other according to ACS guidelines
SC other baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec., in accordance with American Cancer 
Society guidelines
SD 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
TN 1 baseline for ages 35-39, every two years for 40s, each year 
50+, or physician rec.
TX other annual for 35+
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    Table 7 continued         
UT N/A none 
VA 1 baseline for ages 35-39, every two years for 40s, each year 
50+ 
VT other annual for 50+, physician rec for under 50
WA 4 if recommended
WI other two exams total for ages 45-49, each year 50+ 
WV 1 baseline for ages 35-39, every two years for 40s 
WY N/A none 
 
 
Legend: 
1 baseline for ages 35-39, every two years for 40s, each year 50+, or physician rec.  
3 baseline for ages 35-39, every 1-2 years for 40s, each year 50+  
4 if recommended 
5 baseline for ages 35-39 and annual for 40+ 
6 every two years for 40s, each years for 50+ 
 
Chart Source: National Conference of State Legislatures, Health Policy Tracking Service, 
10/02/00  
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